Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 1/20 | 0.39 |
| ▸ | KLK1 | P06870 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489229 | 0.90 | ALDH1A1 (0.46) | KMT2AGRM4MEN1ALDH1A1GAA | |
| SCHEMBL16489211 | 0.90 | GRM4 (0.55) | KMT2AGRM4ALDH1A1GAAMAPT | |
| SCHEMBL16489220 | 0.89 | GRM4 (0.40) | KMT2AGRM4MEN1ALDH1A1GAA | |
| SCHEMBL16489241 | 0.89 | MAPT (0.46) | KMT2AGRM4MEN1ALDH1A1TP53 | |
| SCHEMBL16489224 | 0.89 | GRM4 (0.41) | KMT2AGRM4MEN1ALDH1A1MAPT | |
| SCHEMBL16489209 | 0.88 | NPC1 (0.52) | KMT2AALDH1A1LMNANPC1TSHR | |
| SCHEMBL16491917 | 0.85 | KMT2A (0.50) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL16491926 | 0.83 | NPC1 (0.54) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL16489215 | 0.81 | MAPT (0.45) | KMT2AMEN1MAPTGPR6L3MBTL1 | |
| SCHEMBL16489214 | 0.80 | SMN1; SMN2 (0.41) | KMT2AALDH1A1TP53GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653673-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-20180161312-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | US | disclosed |
| US-20180161312-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | US | disclosed |
| US-9974775-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-22 | — | — | US | disclosed |
| US-9974775-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-22 | — | — | US | disclosed |
| US-20160310468-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-27 | — | — | US | disclosed |
| US-20160310468-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-27 | — | — | US | disclosed |
| US-9453002-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| US-9453002-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| US-20150051225-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051225-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051225-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1S | KMT2A 3077/4885GRM4 472/4885MEN1 660/4885 |
| US-10653673-B2 | Substituted imidazoles as N-type calcium channel blockers | CACNA1B, CACNA1E, CACNA1S | KMT2A 3077/4885GRM4 472/4885MEN1 660/4885 |
| US-20180161312-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1S | KMT2A 3077/4885GRM4 472/4885MEN1 660/4885 |
| US-20160310468-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1S | KMT2A 3077/4885GRM4 472/4885MEN1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.